Clinical trial
A 3-month Safety Evaluation Extension to the 12-week E004-C Study in Asthma Patients (A Double Blinded, Placebo-controlled, Parallel, 3-month Safety Study in Adolescent and Adult Patients With Asthma)
NCT01476904 is registered in ClinicalTrials.gov with Amphastar Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 3-month Safety Evaluation Extension to the 12-week E004-C Study in Asthma Patients (A Double Blinded, Placebo-controlled, Parallel, 3-month Safety Study in Adolescent and Adult Patients With Asthma)
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- July 31, 2012
- Enrollment
- 208 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.